Introduction

Athletes and active people often ask whether there is a non-surgical option for worn or painful joints that does not require time off for a major procedure. This article focuses on the ChondroFiller injection — a non-surgical, ultrasound-guided outpatient treatment — and where it may fit for active individuals, with realistic expectations throughout. For those with larger or more complex cartilage defects where injection alone may not be appropriate, a separate surgical pathway exists; that is addressed in the context of treatment planning below.

Joint Stress in Sport

Sports such as football, basketball and running place repeated load on the joints, which over time can wear the cartilage that cushions articulating surfaces. Athletes want to restore function and return to training as quickly and safely as possible, which makes non-surgical options of interest when they are appropriate. The key question at assessment is the size, depth and location of any cartilage damage, because these factors determine whether a non-surgical injection is adequate or whether a surgical approach is warranted.

What Is the ChondroFiller Injection?

ChondroFiller is a CE-marked Class III medical device: an acellular (cell-free) type I collagen hydrogel scaffold made by Meidrix Biomedicals (Germany) and imported into the UK under prescription. When delivered as an outpatient injection under ultrasound guidance, the gel is placed directly into the joint, where it may settle over worn surfaces to add a protective collagen layer that helps cushion the joint and reduce grinding. The scaffold self-gels within approximately three to five minutes and is designed to recruit the patient's own progenitor cells to support tissue regeneration.

Its mechanical properties allow it to absorb load and adapt to forces within the joint (Weizel et al., 2020). It has biological potential, but it is best understood as a supportive, joint-preserving injection — not a guaranteed repair, cure or reversal of arthritis. The CE marking and the published outcome and safety data belong to ChondroFiller as a device.

Why the Injection Appeals to Active People

As a non-surgical outpatient injection, ChondroFiller does not require theatre time, a general anaesthetic or an incision. There is no surgical recovery period: patients can typically ease back into activity as guided by their clinician. This makes it an option of interest for active individuals with accessible lesions or smaller areas of wear who wish to preserve the joint without committing to surgery.

Responses vary between individuals, and benefits cannot be guaranteed. An active person with joint wear from repeated impact might consider it to help support the joint while remaining active, subject to a careful clinical assessment confirming it is appropriate for their specific pattern of damage.

When Surgery May Be the Right Pathway Instead

Not all cartilage damage is suitable for an injection approach. Where defects are larger, involve load-bearing surfaces such as the knee or hip, or are located in areas less accessible to ultrasound-guided injection, a surgical approach may be more appropriate. At the London Cartilage Clinic, Professor Paul Y. F. Lee performs the Liquid Cartilage surgical protocol — a keyhole (arthroscopic) procedure that delivers the ChondroFiller scaffold together with biological adjuncts such as platelet-rich fibrin or platelet-rich plasma, and where indicated the patient's own mesenchymal stem cells from bone-marrow concentrate. Liquid Cartilage is genuine keyhole surgery requiring theatre and anaesthetic, and it is a distinct pathway from the ChondroFiller injection. Knowing which pathway is appropriate is the purpose of the initial assessment.

Clinical Evidence

Published clinical data for ChondroFiller as a device show an IKDC functional improvement of approximately 30 points over 12 to 36 months in knee studies, with MRI-based MOCART repair scores around 80 and above at follow-up. In a series reporting on the trapeziometacarpal joint — a small hand joint relevant to athletes with thumb problems — ChondroFiller liquid was associated with pain relief and functional improvement (Corain et al., 2023). These figures relate to ChondroFiller the device and scaffold; they are not exclusive to any single delivery route.

As with all regenerative treatments, individual outcomes depend on the size and grade of the lesion, the joint affected, the patient's age and activity level, and the quality of rehabilitation. Evidence suggests benefit for appropriately selected patients, not for every presentation.

Assessment and Next Steps

A thorough assessment is the starting point. Imaging — typically MRI — is used to characterise the lesion and confirm whether the injection pathway or surgical pathway is more appropriate. At the London Cartilage Clinic, individual assessment and tailored advice are provided with realistic expectations, and the choice between non-surgical injection and surgery is made on clinical grounds, not convenience. Anyone considering ChondroFiller for joint wear is encouraged to seek a specialist assessment before proceeding.

References

• Weizel, A., Distler, T., Schneidereit, D., & Friedrich, O. (2020). Complex mechanical behavior of human articular cartilage and hydrogels for cartilage repair. Acta Biomaterialia.
• Corain, M., Zanotti, F., Giardini, M., Gasperotti, L., Invernizzi, E., Biasi, V., & Lavagnolo, U. (2023). The use of an acellular collagen matrix ChondroFiller Liquid for trapeziometacarpal osteoarthritis. Cartilage.